Evidence map›Paper›PMID 38103099›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil.

Iwyson Henrique Fernandes da Costa, Cristiane Aparecida Menezes de Pádua, Paula Lana de Miranda Drummond, Lívia Pena Silveira, Jéssica Soares Malta, Roberta Márcia Marques Dos Santos, Adriano Max Moreira Reis

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Iwyson Henrique Fernandes da CostaPrograma de pós-graduação em medicamentos e assistência farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. iwyson@gmail.com.
Cristiane Aparecida Menezes de PáduaPrograma de pós-graduação em medicamentos e assistência farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Paula Lana de Miranda DrummondPrograma de pós-graduação em medicamentos e assistência farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Lívia Pena SilveiraHospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Jéssica Soares MaltaFaculdade de Farmácia da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Roberta Márcia Marques Dos SantosFundação Ezequiel Dias, Belo Horizonte, Minas Gerais, Brazil.
Adriano Max Moreira ReisPrograma de pós-graduação em medicamentos e assistência farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Universidade Federal de Minas Gerais · BREzequiel Dias Foundation · BRHospital das Clínicas da Universidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of immunomodulators in the treatment of multiple myeloma (MM) patients has been associated with venous thromboembolism (VTE). Due to the increase in mortality of cancer patients, venous thromboembolism is an important concern for newly diagnosed multiple myeloma (NDMM) patients. The aim of this study was to determine the incidence of thromboembolic events and evaluate associated risk factors among Brazilian NDMM patients using immunomodulators.

methodsReal-life retrospective cohort study in two Brazilian institutions with newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulators from January 2009 to December 2019. Data was collected from patients' medical records for the period of 1 year, and Cox regression was performed to identify risk factors on the development of VTE.

resultsWe included 131 patients of which there was a mean age of 61.5 years (SD 11.3), 51.9% female, and predominantly using thalidomide (97.7%) as immunomodulator. We found 9 VTE episodes among our patients, with a 12-month cumulative incidence of 6.97% (95% CI 3.41-12.24). Associated factors after multivariate analysis were recent sepsis, recent traumatic injury, previous VTE, and thromboprophylaxis.

conclusionOur real-life retrospective cohort presented a low incidence of VTE among Brazilian NDMM patients treated with immunomodulators.

Indexed as

Multiple MyelomaVenous ThromboembolismAdjuvants, ImmunologicAnticoagulantsBrazilFemaleHumansImmunologic FactorsImmunomodulating AgentsIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsAdjuvants, ImmunologicAnticoagulantsImmunologic FactorsImmunomodulating AgentsImmunomodulatorsMultiple myelomaVenous thromboembolism

Identifiers

PMID38103099
OpenAlexW4389836910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.